98%
921
2 minutes
20
: Pachychoroid neovasculopathy (PNV) is a pachychoroid-spectrum disease. As blood circulation throughout the choroid may be involved in PNV pathogenesis, analysis using ultra-wide-field (UWF) fundus imaging is crucial. We evaluated choroidal thickness after half-fluence photodynamic therapy (PDT) combined with intravitreal aflibercept injection for PNV using UWF swept-source optical coherence tomography. : Seventeen eyes with PNV that underwent half-fluence PDT with an adjuvant single intravitreal aflibercept injection were analyzed. To compare choroidal thicknesses in the central and peripheral choroids, we set subfields <3, <9, and 9-18 mm from the fovea. The <9 and 9-18 mm subfields were divided into four quadrants. : Choroidal thickness in each subfield decreased significantly after half-fluence PDT ( < 0.001); this reduction was more pronounced in the central area. We also investigated the relationship between the dominant side of the deep choroidal veins that harbor choroidal vein efflux from the macula. When choroidal thickness in the supratemporal and infratemporal 9 mm subfields were evaluated, the ratio of choroidal thickness reduction was not significantly different between the dominant and non-dominant sides. The dominant side was not associated with the extent of choroidal thickness reduction in PNV. : Half-fluence PDT caused thinning of the entire choroid, especially in the central area, in PNV.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10971741 | PMC |
http://dx.doi.org/10.3390/jcm13061608 | DOI Listing |
Retin Cases Brief Rep
September 2025
Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California of Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, California, United States.
Purpose: To describe a case of recalcitrant bilateral peripapillary pachychoroid syndrome (PPS) treated with high-dose (HD) intravitreal aflibercept injections.
Methods: Medical and imaging records were retrospectively evaluated. Multimodal imaging included ultra-widefield indocyanine green and fluorescein angiography and fundus autofluorescence.
Eye (Lond)
September 2025
Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.
Objective: To compare the effectiveness of intravitreal faricimab and aflibercept injections in patients with polypoidal choroidal vasculopathy (PCV).
Methods: This retrospective study analysed 111 treatment-naïve eyes (111 patients) with PCV who received intravitreal injections of either faricimab (30 eyes) or aflibercept (81 eyes). All patients were treated with three initial monthly loading injections.
Retina
September 2025
School of Mathematical and Computational Sciences, University of Prince Edward Island, Charlottetown, Canada.
Purpose: Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal VEGF levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept vs.
View Article and Find Full Text PDFPurpose: To assess how transitioning from an Aflibercept to a Faricimab intravitreal treatment impacts retinal structures and functional aspects in patients with neovascular age related macular degeneration (nAMD) in a real-life setting.
Patients And Methods: A retrospective clinical study including 49 patients (57 eyes) with nAMD at the Department of Ophthalmology and Optometry, Kepler University Hospital, Linz, Austria was performed. The patients, who had previously been receiving monthly Aflibercept injections with an unsatisfactory treatment response, were switched to intravitreal Faricimab and followed-up between 12/2022 and 12/2023.
Diabetes Res Clin Pract
September 2025
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:
Aims: To evaluate the association between intravitreal anti-VEGF therapy and lower extremity complications in diabetic eye disease (DED), and compare risks among ranibizumab, aflibercept, and bevacizumab.
Methods: This retrospective cohort study used a U.S.